Kraig Biocraft Laboratories Announces New Spider Silk Parental Strain for Expanded Commercial Production
ANN ARBOR, Mich., May 28, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces today the successful development of a new recombinant spider silk parental line, purpose-built for large-scale commercial production.
This newly developed strain represents the third commercial production line created by Kraig Labs as it executes on its strategy to expand output capacity. The addition of this next-generation silk-producing line comes as the Company ramps up production to fulfill current material requests and strategically build inventory for future sales.
"Our team continues to deliver on key milestones as we scale the commercialization of spider silk," said Company Founder and CEO, Kim Thompson. "With the development of this new production strain, we are not only increasing our ability to meet existing demand, but also reinforcing the foundation for our future growth. This new strain is part of the production roadmap we outlined in 2024 and a key part of our transition to a full double hybrid production system."
This latest strain is part of Kraig Labs' broader development pipeline, which includes several additional parental lines currently in advanced stages of development. These lines are designed to enable a transition to a double hybrid production model—expected to deliver significant performance improvements, including higher silk yields, increased colony resilience, and reduced overall production costs.
"As we prepare to implement double hybrid crosses into our production platform, we are opening the door to greater scalability, efficiency, and product consistency," Thompson continued. "This is a key step forward in our mission to bring the power of spider silk to mainstream markets."
The Company is continuing its focus on building a robust and scalable production system as it transitions from pilot operations to full-scale manufacturing.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward-looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.(720) 288-8495ir@KraigLabs.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
10 minutes ago
- Business Wire
i3 Verticals Announces Earnings Release and Conference Call Date for Third Quarter of Fiscal 2025
NASHVILLE, Tenn.--(BUSINESS WIRE)--i3 Verticals, Inc. (Nasdaq: IIIV) ('i3 Verticals' or the 'Company'), announced today that it will release its financial results for the third quarter ended June 30, 2025, on Thursday, August 7, 2025, after the Nasdaq market close. The Company will also host a conference call on Friday, August 8, 2025, at 8:30 a.m. EDT to discuss financial results and operations. To listen to the call live via telephone, participants should dial (844) 887-9399 approximately 10 minutes prior to the start of the call. A telephonic replay will be available from 11:30 a.m. EDT on August 8, 2025, through August 15, 2025, by dialing (877) 344-7529 and entering Confirmation Code 4426770. To listen to the call live via webcast, participants should visit the 'Investors' section of the Company's website, and go to the 'Events & Presentations' page approximately 10 minutes prior to the start of the call. The online replay will be available on this page of the Company's website beginning shortly after the conclusion of the call and will remain available for 30 days. About i3 Verticals The Company provides innovative software and services solutions to its public sector customers. These comprehensive solutions cover a broad range of applications, including cloud native enterprise software, all of which enable state and local governments and related agencies to serve their constituents in an efficient and seamless manner. With thousands of software installations across all 50 states and Canada, i3 Verticals is a leader in the public sector vertical. More information about the Company can be found at
an hour ago
UnitedHealth under federal investigation, company says in filing
UnitedHealth Group faces a criminal and civil investigation from the Department of Justice, the company disclosed on Thursday. The company in an SEC filing said it was complying with the requests from the DOJ. UnitedHealth said it reached out "proactively" to the DOJ after media reports about a probe into its Medicare practices. "The Company has now begun complying with formal criminal and civil requests from the Department. The Company has full confidence in its practices and is committed to working cooperatively with the Department throughout this process," UnitedHealth said. UnitedHealth's announcement that it faces a federal investigation adds to an increasingly tumultuous year for the country's largest healthcare company. The company was thrown into the spotlight after last year's fatal shooting of UnitedHealthcare CEO Brian Thompson in New York, sparking a national conversation about frustrations with healthcare companies. UnitedHealth Group's CEO abruptly left the company in May, and the company's stock price plunged following a series of reports in The Wall Street Journal about civil and criminal probes into the company. The WSJ reported in May that the DOJ's healthcare-fraud unit was investigating possible Medicare fraud at the company, adding to investigations of potential antitrust violations and its Medicare billing practices. The company was the worst performer on the Dow Jones Industrial Average during the first half of 2025. Its stock price declined by 1.5 percent in morning trading following the announcement. In a filing with the Securities and Exchange Commission, UnitedHealth said it has "full confidence" in its practices. It added that a court-appointed monitor found no wrongdoing after a decade-long probe into its Medicare Advantage business. "The Company is committed to maintaining the integrity of its business practices and serving as reliable stewards of American tax dollars," UnitedHealth said.
Business Upturn
2 hours ago
- Business Upturn
Regenx Tech Provides Operational Update
EDMONTON, Alberta, July 24, 2025 (GLOBE NEWSWIRE) — Regenx Tech Corp. ('Regenx' or the 'Company') (CSE: RGX) (OTCQB: RGXTF) (FSE: YRS; WKN: A2DSW3) is pleased to provide an update on the commissioning of its newly upgraded facility in Newport, Tennessee. The Company has successfully completed water testing, a key phase in the restart process that confirms full system integration with the newly installed air purification system. This critical step was made possible following the receipt of final air permits. Advertisement 'We are thrilled to reach this stage,' said Rick Purdy, President of Regenx USA. 'The successful water test validates the extensive process enhancements we've implemented and marks a major step forward in our restart strategy. Our teams have worked tirelessly to get us here, and momentum continues to build.' Regenx is now conducting a full system test with chemistry, including equipment calibration and optimization. This represents the final protocol in the commissioning process and will pave the way for commercial production to resume. The Company will continue to provide updates on: Completion of commissioning Initiation of startup Ramp-up to full-scale production As Regenx advances toward its operational goals, the Company remains focused on delivering a clean, sustainable, and economically viable solution for recovering platinum and palladium from end-of-life diesel catalytic converters. For further information contact: REGENX TECH CORP. [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
